Aileron Therapeutics Ownership 2024 | Who Owns Aileron Therapeutics Now?
Institutional Ownership
0.00%
Insider Ownership
0.65%
Retail Ownership
99.35%
Institutional Holders
1.00
Aileron Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
HEXAGON CAPITAL PARTNERS LLC | 0.00% | 0.00% | 213 | 213 | 100.00% | 591 | Jun 30, 2024 |
Aileron Therapeutics's largest institutional shareholder is HEXAGON CAPITAL PARTNERS LLC, holding 0.00% of the company's total share outstanding, currently valued at $591.00. The top 10 institutional shareholders own together 0.00% of the company.
Institutional Shareholders by % of Total Assets
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
HEXAGON CAPITAL PARTNERS LLC | 0.00% | 0.00% | 213 | 213 | 100.00% | 591 | Jun 30, 2024 |
The largest Aileron Therapeutics shareholder by % of total assets is HEXAGON CAPITAL PARTNERS LLC. The company owns 213.00 shares of Aileron Therapeutics (ALRN), representing 0.00% of its total assets.
Institutional Buyers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
HEXAGON CAPITAL PARTNERS LLC | 0.00% | 0.00% | 213 | 213 | 100.00% | 591 | Jun 30, 2024 |
As of Jun 30 2024, Aileron Therapeutics's largest institutional buyer is HEXAGON CAPITAL PARTNERS LLC. The company purchased 213.00 stocks of ALRN, valued at $591.00.
Institutional Sellers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
HEXAGON CAPITAL PARTNERS LLC | 0.00% | 0.00% | 213 | 213 | 100.00% | 591 | Jun 30, 2024 |
As of Jun 30 2024, Aileron Therapeutics's biggest institutional seller is HEXAGON CAPITAL PARTNERS LLC. The company sold 213.00 shares of ALRN, valued at $591.00.
Institutional New positions
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
HEXAGON CAPITAL PARTNERS LLC | 0.00% | 0.00% | 213 | 213 | 100.00% | 591 | Jun 30, 2024 |
Aileron Therapeutics's largest new institutional shareholder by number of shares is HEXAGON CAPITAL PARTNERS LLC, purchased 213.00 shares, valued at $591.00, as of undefined.
Institutional Sold Out
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|
Aileron Therapeutics Mutual Fund Holders
Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
---|---|---|---|---|---|
PRUDENTIAL SECTOR FUNDS, INC. | 0.43% | 895,522 | - | - | Feb 29, 2024 |
FIDELITY COMMONWEALTH TRUST | 0.09% | 285,973 | - | - | Feb 29, 2024 |
PRUDENTIAL SECTOR FUNDS, INC. | 0.02% | 44,776 | - | - | Feb 29, 2024 |
FIDELITY COMMONWEALTH TRUST | 0.01% | 39,985 | 11,726 | 41.49% | Feb 29, 2024 |
VANGUARD INDEX FUNDS | 0.01% | 2,517,325 | - | - | Mar 31, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 555,218 | - | - | Feb 29, 2024 |
VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 60,241 | - | - | Mar 31, 2024 |
NATIONWIDE MUTUAL FUNDS | 0.00% | 128,010 | - | - | Jan 31, 2024 |
SCHWAB CAPITAL TRUST | 0.00% | 27,406 | - | - | Feb 29, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 28,088 | 692 | 2.53% | Feb 29, 2024 |
VANGUARD INDEX FUNDS | 0.00% | 40,314 | -40,314 | -50.00% | Mar 31, 2024 |
VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 1,770 | - | - | Mar 31, 2024 |
USAA MUTUAL FUNDS TRUST | 0.00% | 9,315 | - | - | Jan 31, 2024 |
EQ ADVISORS TRUST | 0.00% | 14,981 | - | - | Mar 31, 2024 |
iSHARES TRUST | 0.00% | 175,420 | - | - | Mar 31, 2024 |
JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 4,229 | - | - | Mar 31, 2024 |
Blackstone Alternative Investment Funds | 0.00% | 2,600 | 2,600 | - | Mar 31, 2021 |
Aileron Therapeutics's largest mutual fund holder by % of total assets is "PRUDENTIAL SECTOR FUNDS, INC.", owning 895.52K shares, compromising 0.43% of its total assets.
Aileron Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
Date | Holdings | Change % |
---|---|---|
30 Jun, 24 | 1 | - |
30 Sep, 22 | 28 | -17.65% |
30 Jun, 22 | 34 | -12.82% |
31 Mar, 22 | 39 | -4.88% |
31 Dec, 21 | 41 | - |
30 Sep, 21 | 41 | -10.87% |
30 Jun, 21 | 46 | -9.80% |
31 Mar, 21 | 51 | 75.86% |
31 Dec, 20 | 29 | 16.00% |
30 Sep, 20 | 25 | -7.41% |
30 Jun, 20 | 27 | 58.82% |
31 Mar, 20 | 17 | - |
31 Dec, 19 | 17 | -5.56% |
30 Sep, 19 | 18 | -5.26% |
30 Jun, 19 | 19 | - |
31 Mar, 19 | 19 | -5.00% |
31 Dec, 18 | 20 | -9.09% |
30 Sep, 18 | 22 | 22.22% |
30 Jun, 18 | 18 | -33.33% |
31 Mar, 18 | 27 | -18.18% |
31 Dec, 17 | 33 | 6.45% |
30 Sep, 17 | 31 | 63.16% |
30 Jun, 17 | 19 | - |
As of 30 Jun 24, 1 institutions are holding Aileron Therapeutics's shares, representing an increase of 0.00% compared to the previous quarter.
Shares Outstanding Trend
Date | Shares Outstanding | Change % |
---|---|---|
30 Jun, 24 | 213 | - |
30 Sep, 22 | 28,290,891 | -11.81% |
30 Jun, 22 | 32,080,815 | -0.38% |
31 Mar, 22 | 32,202,779 | -4.04% |
31 Dec, 21 | 33,559,181 | 1.99% |
30 Sep, 21 | 32,904,433 | -0.87% |
30 Jun, 21 | 33,192,299 | -1.08% |
31 Mar, 21 | 33,556,281 | 222.44% |
31 Dec, 20 | 10,406,983 | 272.87% |
30 Sep, 20 | 2,791,017 | -29.18% |
30 Jun, 20 | 3,940,725 | 101.82% |
31 Mar, 20 | 1,952,585 | 16.78% |
31 Dec, 19 | 1,672,082 | -52.73% |
30 Sep, 19 | 3,536,991 | -51.08% |
30 Jun, 19 | 7,229,430 | 14.37% |
31 Mar, 19 | 6,320,988 | 364.74% |
31 Dec, 18 | 1,360,119 | -27.45% |
30 Sep, 18 | 1,874,862 | 109.94% |
30 Jun, 18 | 893,054 | -14.49% |
31 Mar, 18 | 1,044,374 | -6.94% |
31 Dec, 17 | 1,122,263 | -4.37% |
30 Sep, 17 | 1,173,497 | -36.89% |
30 Jun, 17 | 1,859,378 | - |
Aileron Therapeutics (ALRN) has 213.00 shares outstanding as of 30 Jun 24, up 0.00% compared to the previous quarter.
Institutional Ownership Trend
Date | Ownership % | Change % |
---|---|---|
30 Jun, 24 | 0.00% | - |
30 Sep, 22 | 31.15% | 2.50% |
30 Jun, 22 | 35.32% | 2.80% |
31 Mar, 22 | 35.52% | 2.49% |
31 Dec, 21 | 37.79% | 2.86% |
30 Sep, 21 | 36.34% | 2.70% |
30 Jun, 21 | 36.69% | 2.27% |
31 Mar, 21 | 40.24% | 25.84% |
31 Dec, 20 | 12.48% | 111.40% |
30 Sep, 20 | 3.35% | 14.99% |
30 Jun, 20 | 4.73% | 86.19% |
31 Mar, 20 | 2.34% | 58.24% |
31 Dec, 19 | 2.01% | 11.14% |
30 Sep, 19 | 4.24% | 5.64% |
30 Jun, 19 | 8.67% | 15.09% |
31 Mar, 19 | 7.58% | 284.92% |
31 Dec, 18 | 1.63% | 32.27% |
30 Sep, 18 | 2.25% | 196.02% |
30 Jun, 18 | 1.07% | 68.27% |
31 Mar, 18 | 1.25% | 69.14% |
31 Dec, 17 | 1.35% | 67.95% |
30 Sep, 17 | 1.41% | 28.30% |
30 Jun, 17 | 2.23% | - |
As of 30 Jun 24, Aileron Therapeutics is held by 0.00% institutional shareholders, representing a 0.00% growth compared to 30 Sep 22.
Institutional Increased Positions Trend
Date | Increased Positions | Change % |
---|---|---|
30 Jun, 24 | 1 | - |
30 Sep, 22 | 11 | - |
30 Jun, 22 | 11 | - |
31 Mar, 22 | 11 | -47.62% |
31 Dec, 21 | 21 | 31.25% |
30 Sep, 21 | 16 | -20.00% |
30 Jun, 21 | 20 | -45.95% |
31 Mar, 21 | 37 | 105.56% |
31 Dec, 20 | 18 | 20.00% |
30 Sep, 20 | 15 | -25.00% |
30 Jun, 20 | 20 | 233.33% |
31 Mar, 20 | 6 | -40.00% |
31 Dec, 19 | 10 | 42.86% |
30 Sep, 19 | 7 | -30.00% |
30 Jun, 19 | 10 | - |
31 Mar, 19 | 10 | -9.09% |
31 Dec, 18 | 11 | -42.11% |
30 Sep, 18 | 19 | 90.00% |
30 Jun, 18 | 10 | -23.08% |
31 Mar, 18 | 13 | -38.10% |
31 Dec, 17 | 21 | -4.55% |
30 Sep, 17 | 22 | 15.79% |
30 Jun, 17 | 19 | - |
1 institutional shareholders have increased their position in ALRN stock as of 30 Jun 24 compared to 11 in the previous quarter (a 0.00% increase).
Institutional Reduced Positions Trend
Date | Reduced Positions | Change % |
---|---|---|
30 Jun, 24 | - | - |
30 Sep, 22 | 4 | -42.86% |
30 Jun, 22 | 7 | -41.67% |
31 Mar, 22 | 12 | 50.00% |
31 Dec, 21 | 8 | -11.11% |
30 Sep, 21 | 9 | 12.50% |
30 Jun, 21 | 8 | 166.67% |
31 Mar, 21 | 3 | -25.00% |
31 Dec, 20 | 4 | 33.33% |
30 Sep, 20 | 3 | 50.00% |
30 Jun, 20 | 2 | -66.67% |
31 Mar, 20 | 6 | 200.00% |
31 Dec, 19 | 2 | -50.00% |
30 Sep, 19 | 4 | -20.00% |
30 Jun, 19 | 5 | -16.67% |
31 Mar, 19 | 6 | -14.29% |
31 Dec, 18 | 7 | 250.00% |
30 Sep, 18 | 2 | -60.00% |
30 Jun, 18 | 5 | -44.44% |
31 Mar, 18 | 9 | 80.00% |
31 Dec, 17 | 5 | 25.00% |
30 Sep, 17 | 4 | - |
30 Jun, 17 | - | - |
- institutional shareholders have reduced their position in ALRN stock as of 30 Jun 24 compared to 4 in the previous quarter (a 0.00% increase).
All Institutional Ownership Trend Data
Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
---|---|---|---|---|---|---|---|---|---|---|
30 Jun, 24 | 1 | - | 213 | - | 0.00% | - | 1 | - | - | - |
30 Sep, 22 | 28 | -17.65% | 28,290,891 | -11.81% | 31.15% | 2.50% | 11 | - | 4 | -42.86% |
30 Jun, 22 | 34 | -12.82% | 32,080,815 | -0.38% | 35.32% | 2.80% | 11 | - | 7 | -41.67% |
31 Mar, 22 | 39 | -4.88% | 32,202,779 | -4.04% | 35.52% | 2.49% | 11 | -47.62% | 12 | 50.00% |
31 Dec, 21 | 41 | - | 33,559,181 | 1.99% | 37.79% | 2.86% | 21 | 31.25% | 8 | -11.11% |
30 Sep, 21 | 41 | -10.87% | 32,904,433 | -0.87% | 36.34% | 2.70% | 16 | -20.00% | 9 | 12.50% |
30 Jun, 21 | 46 | -9.80% | 33,192,299 | -1.08% | 36.69% | 2.27% | 20 | -45.95% | 8 | 166.67% |
31 Mar, 21 | 51 | 75.86% | 33,556,281 | 222.44% | 40.24% | 25.84% | 37 | 105.56% | 3 | -25.00% |
31 Dec, 20 | 29 | 16.00% | 10,406,983 | 272.87% | 12.48% | 111.40% | 18 | 20.00% | 4 | 33.33% |
30 Sep, 20 | 25 | -7.41% | 2,791,017 | -29.18% | 3.35% | 14.99% | 15 | -25.00% | 3 | 50.00% |
30 Jun, 20 | 27 | 58.82% | 3,940,725 | 101.82% | 4.73% | 86.19% | 20 | 233.33% | 2 | -66.67% |
31 Mar, 20 | 17 | - | 1,952,585 | 16.78% | 2.34% | 58.24% | 6 | -40.00% | 6 | 200.00% |
31 Dec, 19 | 17 | -5.56% | 1,672,082 | -52.73% | 2.01% | 11.14% | 10 | 42.86% | 2 | -50.00% |
30 Sep, 19 | 18 | -5.26% | 3,536,991 | -51.08% | 4.24% | 5.64% | 7 | -30.00% | 4 | -20.00% |
30 Jun, 19 | 19 | - | 7,229,430 | 14.37% | 8.67% | 15.09% | 10 | - | 5 | -16.67% |
31 Mar, 19 | 19 | -5.00% | 6,320,988 | 364.74% | 7.58% | 284.92% | 10 | -9.09% | 6 | -14.29% |
31 Dec, 18 | 20 | -9.09% | 1,360,119 | -27.45% | 1.63% | 32.27% | 11 | -42.11% | 7 | 250.00% |
30 Sep, 18 | 22 | 22.22% | 1,874,862 | 109.94% | 2.25% | 196.02% | 19 | 90.00% | 2 | -60.00% |
30 Jun, 18 | 18 | -33.33% | 893,054 | -14.49% | 1.07% | 68.27% | 10 | -23.08% | 5 | -44.44% |
31 Mar, 18 | 27 | -18.18% | 1,044,374 | -6.94% | 1.25% | 69.14% | 13 | -38.10% | 9 | 80.00% |
31 Dec, 17 | 33 | 6.45% | 1,122,263 | -4.37% | 1.35% | 67.95% | 21 | -4.55% | 5 | 25.00% |
30 Sep, 17 | 31 | 63.16% | 1,173,497 | -36.89% | 1.41% | 28.30% | 22 | 15.79% | 4 | - |
30 Jun, 17 | 19 | - | 1,859,378 | - | 2.23% | - | 19 | - | - | - |
Aileron Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
---|
Insider Sells
All Insider Owners Trades
The last insider sell of Aileron Therapeutics's stock was made by UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO on Jun 17 2024, selling 1,900 shares at $3.30 per share (valued at $6.27K).
Aileron Therapeutics Insider Ownership Trends
All Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q2 2024 | - | 53 | - |
Q1 2024 | 5 | 4 | 125.00% |
Q4 2023 | 4 | 8 | 50.00% |
Q2 2022 | 8 | - | - |
Q1 2022 | 10 | - | - |
Q2 2021 | 10 | - | - |
Q1 2021 | 1 | - | - |
Q2 2020 | 10 | - | - |
Q1 2020 | 4 | 1 | 400.00% |
Q4 2019 | 3 | - | - |
Q3 2019 | 8 | - | - |
Q2 2019 | 14 | 3 | 466.67% |
Q1 2019 | 1 | 5 | 20.00% |
Q4 2018 | 1 | 5 | 20.00% |
Q3 2018 | 2 | 24 | 8.33% |
Q2 2018 | 10 | 14 | 71.43% |
Q1 2018 | 1 | 1 | 100.00% |
Q3 2017 | 44 | 60 | 73.33% |
Q2 2017 | 1 | 60 | 1.67% |
Q2 2012 | 1 | - | - |
0 total buy trades, and 53 total sell trades (buy/sell ratio of 0.00%) were made by Aileron Therapeutics's insiders, as of Q2 2024.
Open Market Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q2 2024 | - | 52 | - |
Q1 2024 | - | - | - |
Q4 2023 | 2 | - | - |
Q2 2022 | - | - | - |
Q1 2022 | - | - | - |
Q2 2021 | - | - | - |
Q1 2021 | 1 | - | - |
Q2 2020 | 3 | - | - |
Q1 2020 | - | - | - |
Q4 2019 | 3 | - | - |
Q3 2019 | 8 | - | - |
Q2 2019 | - | 1 | - |
Q1 2019 | - | 4 | - |
Q4 2018 | - | - | - |
Q3 2018 | 1 | 22 | 4.55% |
Q2 2018 | 3 | 14 | 21.43% |
Q1 2018 | - | 1 | - |
Q3 2017 | 15 | - | - |
Q2 2017 | - | - | - |
Q2 2012 | - | - | - |
As of Q2 2024, Insider owners conducted 0 open market buy trades and 52 open market sell trades of Aileron Therapeutics's stocks.
Aileron Therapeutics Peer Ownership
Ticker | Company |
---|---|
GOVX | GeoVax Labs, Inc. |
NUVB | Nuvation Bio Inc. |
MGTA | Dianthus Therapeutics, Inc. |
ABVC | ABVC BioPharma, Inc. |
HSTO | Histogen Inc. |
SABS | SAB Biotherapeutics, Inc. |
BPTH | Bio-Path Holdings, Inc. |
CTMX | CytomX Therapeutics, Inc. |
ARTL | Artelo Biosciences, Inc. |
APTX | Aptinyx Inc. |
FWBI | Entero Therapeutics, Inc. |
EVLO | Evelo Biosciences, Inc. |
VCNX | Vaccinex, Inc. |
ASMB | Assembly Biosciences, Inc. |
CRIS | Curis, Inc. |
SLRX | Salarius Pharmaceuticals, Inc. |
NLTX | Neurogene Inc. |
CBIO | Gyre Therapeutics, Inc. |
BNTC | Benitec Biopharma Inc. |
TIL | Instil Bio, Inc. |
ALRN Ownership FAQ
Who Owns Aileron Therapeutics?
Aileron Therapeutics is owned by institutional shareholders (0.00%), insiders (0.65%), and public (99.35%). The largest institutional shareholder of Aileron Therapeutics is HEXAGON CAPITAL PARTNERS LLC (0.00% of total shares) and the top mutual fund owner is PRUDENTIAL SECTOR FUNDS, INC. (0.43% of total shares).
Who are the major institutional shareholders of Aileron Therapeutics?
Aileron Therapeutics's major institutional shareholders are HEXAGON CAPITAL PARTNERS LLC. The top five shareholders own together 0.00% of the company's share outstanding.
How many Aileron Therapeutics shareholders are there?
As of Jun 2024, there are 1 institutional shareholders of Aileron Therapeutics.
What percentage of Aileron Therapeutics is owned by HEXAGON CAPITAL PARTNERS LLC?
HEXAGON CAPITAL PARTNERS LLC owns 213 shares of Aileron Therapeutics, representing 0.00% of the company's total shares outstanding, valued at $591 (as of Jun 2024).